ImaBiotech website in English


  • ASMS 2017

    Come and meet Rima Ait-Belkacem and Jonathan Stauber to discover all our capabilities. June 4- 8, 2017, in (...)

    Read more
  • Webinar on Immuno-Oncology by Rima AIT-BELKACEM, PhD

    The webinar titled “Immuno-Oncology: Tryptophan-Kynurenine Microenvironment Tumor Metabolites Pathway Highlighted by (...)

    Read more
See all news

Cardiovascular & metabolic diseases

Traditional drug pharmacokinetics and distribution with dissection can now be advantageously replaced by MALDI Imaging Mass Spectrometry, which offers accurate localization and quantitation of parent drugs and metabolites combined with biomarkersin one single sample.

ImaBiotech provides quantitative MALDI Imaging Mass Spectrometry services unmatched by any other classical technique: quantitative label-free distribution in cardiovascular & metabolic diseases with high accuracy up to 20µm resolution.

Artery: Imaging mass spectrometric

Figure : Imaging mass spectrometric analysis of bile acids related ions on rat liver section. Each image is marked with corresponding bile acids species; TCA/THCA, TCDCA/TDCA/ TUDCA, GCA/GHCA and GDCA/GUDCA, with A/B corresponding to isobaric species). HE staining image of the same liver section analyzed in MSI. Red dashed square area indicates portal vein location which co-localized with bile acids species distribution. Scale bar indicates 2 mm. MALDI-FTICRMS image in negative mode at a spatial resolution of 160 µm.

In Cardiovascular therapeutic area, we can study :

Target Engagement with Mass specTarget Engagement

PK PD With Mass spec ImagingPK/PD

Toxicology and Mass spectrometry imagingToxicity effects

Drug distribution and quantification
  • High resolution drug and metabolites imaging at 20µm
  • Quantify drug and metabolites in different regions of the heart, kidney, etc.
  • Coupled with whole body distribution to study overall and organ-specific molecule localization
  • Unknown metabolite research and identification

  • Atherosclerosis
  • Diabetes
  • Metabolic syndrome
  • Obesity
  • Thrombo-embolic diseases

  • Study the impact of treatment onto endogenous metabolites
  • Support the validation of pharmacological animal models

Animal species
  • Guinea pig and mini pig
  • Rabbit
  • Rat
  • Mouse

Kidney Mass spec Imaging